Lipitor vs Amlodipine: Cost and Access Head-to-Head

Why This Is Not an Either/Or Comparison

Atorvastatin and amlodipine act on entirely separate pathways of cardiovascular risk. Atorvastatin inhibits HMG-CoA reductase in the liver, lowering LDL cholesterol by 39% to 60% depending on dose, according to prescribing data reviewed by the FDA [3]. Amlodipine relaxes vascular smooth muscle, reducing systolic blood pressure by an average of 10 to 15 mmHg at standard doses.

Because their mechanisms do not overlap, clinicians rarely choose between them. A patient with isolated hyperlipidemia and normal blood pressure receives atorvastatin alone. A patient with hypertension and normal lipids receives amlodipine alone. The large population of patients who present with both elevated LDL and elevated blood pressure, a pattern the American Heart Association calls "cardiometabolic risk clustering" [4], often takes both medications simultaneously. The ASCOT trial program is itself the best illustration: investigators studied atorvastatin as an add-on to an amlodipine-based blood pressure regimen, not as a replacement for it [1][2].

So the relevant comparison for most patients is not clinical efficacy on a shared endpoint. It is practical: which drug costs less, which is easier to access, and what happens when a patient needs both.

Generic Availability and Retail Cost

Both atorvastatin and amlodipine lost patent exclusivity years ago, making generic versions widely available at rock-bottom prices. Atorvastatin went generic in the United States in November 2011 after Pfizer's Lipitor patent expired. Amlodipine (originally branded as Norvasc, also a Pfizer product) went generic even earlier, in 2007.

At most retail pharmacies today, a 30-day supply of generic atorvastatin 20 mg costs between $4 and $10 without insurance. Generic amlodipine 5 mg runs $4 to $12 for the same quantity. Both drugs appear on the $4 generic lists at Walmart, Costco, and several grocery chain pharmacies. According to GoodRx data aggregated across more than 70,000 U.S. pharmacies, atorvastatin 10 mg ranks among the five cheapest prescription drugs dispensed in the country.

Brand-name Lipitor, when dispensed without generic substitution, carries a cash price between $350 and $450 per month. Brand-name Norvasc runs approximately $150 to $250. In practice, fewer than 2% of atorvastatin prescriptions and fewer than 1% of amlodipine prescriptions are filled as brand-name products, per IQVIA prescription audit data [5]. Generic substitution is automatic in all 50 states unless the prescriber writes "dispense as written."

The cost difference between the two generics is negligible. Neither drug presents a meaningful financial barrier to initiation or long-term adherence for the vast majority of patients.

Insurance Formulary Placement

On commercial insurance plans, both atorvastatin and amlodipine sit on Tier 1, the preferred generic tier with the lowest copay. A typical Tier 1 copay is $0 to $10 per 30-day fill.

Under Medicare Part D, both drugs appear on the formulary of every major plan sponsor surveyed for 2026 coverage. The Centers for Medicare & Medicaid Services confirms that statins receive special formulary protections under the Part D "six protected classes" provision. Statins are not technically one of the six protected classes (those are anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals, and immunosuppressants), but CMS guidance since 2006 has required Part D plans to cover "all or substantially all" statins due to their clinical importance in cardiovascular prevention [6]. Amlodipine, while not in a protected class, is covered universally because of its low cost and decades of generic availability.

For patients on Medicaid, both drugs are covered in every state formulary. No prior authorization is required for either medication at standard doses. High-dose atorvastatin (80 mg) may require step therapy documentation in a small number of state Medicaid programs, but the requirement is minimal: documented trial of a lower dose or clinical justification for high-intensity therapy.

Neither drug requires specialty pharmacy dispensing, REMS enrollment, or refrigerated shipping. Both can be filled at any retail, mail-order, or 90-day pharmacy.

The ASCOT Trial Program: Where These Two Drugs Intersect

The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) is the most clinically relevant evidence base connecting atorvastatin and amlodipine. ASCOT enrolled 19,257 hypertensive patients with at least three additional cardiovascular risk factors across sites in the United Kingdom, Ireland, and Scandinavia.

The trial had two arms running in parallel. ASCOT-BPLA (Blood Pressure Lowering Arm) randomized patients to amlodipine-based therapy (with perindopril added as needed) versus atenolol-based therapy (with bendroflumethiazide added as needed) [2]. Over a median follow-up of 5.5 years, the amlodipine-based regimen reduced all-cause mortality by 11% (P=0.025), stroke by 23% (P=0.0003), and total cardiovascular events by 16% compared to the atenolol arm.

ASCOT-LLA (Lipid-Lowering Arm) took a subset of 10,305 patients with total cholesterol of 6.5 mmol/L or lower and randomized them to atorvastatin 10 mg daily versus placebo [1]. The atorvastatin group experienced a 36% relative reduction in nonfatal MI and fatal CHD (P=0.0005). The trial was stopped 1.7 years early, at a median of 3.3 years, because of the clear benefit signal.

Dr. Peter Sever, the ASCOT principal investigator, stated in the Lancet publication: "These findings suggest that lipid lowering with atorvastatin in hypertensive patients is beneficial even at relatively low cholesterol concentrations" [1]. The trial established the rationale for combination therapy with a statin and an antihypertensive in moderate-risk patients, a practice now embedded in both ACC/AHA [7] and ESC/EAS [8] guideline recommendations.

A post-hoc analysis of ASCOT published in the European Heart Journal in 2018 found that the combination of amlodipine plus atorvastatin produced a 53% reduction in coronary events compared with the atenolol plus placebo group, a benefit larger than either drug alone would predict from simple additive modeling [9].

When Patients Take Both: Combination Products and Adherence

Because the amlodipine-plus-atorvastatin combination is so common, Pfizer developed Caduet, a single-pill combination containing both drugs. The FDA approved Caduet in 2004 for patients who needed treatment for both hypertension and dyslipidemia.

Caduet is available in multiple dose combinations (amlodipine 2.5/5/10 mg with atorvastatin 10/20/40/80 mg). Generic versions of the combination pill became available in 2014. The combination tablet typically costs $15 to $40 per month for the generic, slightly more than filling the two generics separately but offering the convenience of one pill instead of two.

Pill burden matters. A 2019 meta-analysis published in JAMA Internal Medicine found that single-pill combinations improved medication adherence by 26% relative to the same drugs given as separate tablets (odds ratio 1.26, 95% CI 1.14 to 1.38) [10]. For patients taking three or more cardiovascular medications, switching even one pair to a fixed-dose combination reduced discontinuation rates at 12 months.

The clinical significance is real. Dr. Salim Yusuf of McMaster University, lead investigator of the TIPS-3 trial, noted: "The polypill approach reduces the number of decisions a patient has to make each day, and every removed decision is a removed opportunity for non-adherence" [11].

Cost Comparison at Different Doses

Atorvastatin is available in 10, 20, 40, and 80 mg tablets. The generic cost per 30-day supply is nearly flat across doses because all tablet strengths use the same manufacturing process. A 30-day supply of atorvastatin 80 mg costs approximately $6 to $12, only marginally more than the 10 mg dose.

Amlodipine is available in 2.5, 5, and 10 mg tablets. Similarly, the cost difference across strengths is minimal. A 30-day supply of amlodipine 10 mg costs $5 to $14.

This flat pricing curve is unusual in pharmaceuticals and works to the patient's advantage. A clinician can titrate either drug to maximum dose without triggering a significant increase in out-of-pocket cost. Compare this to branded medications where doubling the dose can double the price.

For patients without any insurance coverage, the combined out-of-pocket cost of both drugs at moderate doses (atorvastatin 20 mg + amlodipine 5 mg) runs approximately $8 to $20 per month at discount pharmacies. This positions the combination as one of the most cost-effective cardiovascular regimens available.

Access Barriers: Who Has Trouble Getting These Drugs?

True access barriers for either drug are rare in the U.S. market, but they do exist in specific populations.

Rural pharmacy deserts. The CDC reports that 3.2 million Americans live more than 10 miles from the nearest pharmacy [12]. For these patients, 90-day mail-order fills are the practical solution, and both drugs are eligible for mail-order through every major pharmacy benefit manager.

Uninsured patients without discount access. While both generics are cheap, a patient who does not know about $4 generic programs or manufacturer discount cards may face higher cash prices at independent pharmacies. Mark Cuban Cost Plus Drugs lists atorvastatin 20 mg at $3.60 for a 30-day supply and amlodipine 5 mg at $3.00, both inclusive of pharmacy markup and shipping.

Patients requiring brand-name formulation. Rare patients with documented allergies to specific inactive ingredients in generic formulations may need brand Lipitor or brand Norvasc. These patients face significantly higher costs and may require prior authorization for brand-name dispensing. The number of such patients is very small.

International access. Outside the United States, generic atorvastatin and amlodipine are listed on the WHO Model List of Essential Medicines [13]. Both drugs are manufactured by dozens of generic producers worldwide and are available even in low-income countries, often at less than $1 per month through government procurement programs.

Switching and Therapeutic Substitution

Atorvastatin and amlodipine are not therapeutically interchangeable. They treat different conditions. A pharmacist cannot substitute one for the other, and a clinician would never switch a patient from one to the other as equivalent therapy.

The confusion likely arises because both drugs appeared in the same ASCOT trial and because Caduet packages them together. But their indications are distinct:

Atorvastatin is FDA-approved for primary hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, primary prevention of cardiovascular events in patients with multiple risk factors, and secondary prevention after acute coronary syndrome [3].

Amlodipine is FDA-approved for hypertension, chronic stable angina, and vasospastic (Prinzmetal) angina [14].

If a patient experiences side effects on one drug, the clinician would switch to another agent within the same drug class, not across classes. Statin intolerance (most commonly myalgia) might prompt a switch from atorvastatin to rosuvastatin or pravastatin. Amlodipine-related peripheral edema might prompt a switch to a different calcium channel blocker like felodipine, or to a different antihypertensive class entirely, such as an ACE inhibitor or ARB.

Side Effect Profiles and Their Impact on Long-Term Cost

Side effects can generate hidden costs through additional office visits, lab monitoring, and drug switches. The side effect profiles of these two drugs differ substantially.

Atorvastatin's most common adverse effects include myalgia (occurring in 3% to 5% of patients in clinical trials), elevated hepatic transaminases (0.7% at standard doses), and gastrointestinal symptoms. The American College of Cardiology recommends a baseline lipid panel and liver function tests before starting statin therapy, with repeat lipid panel at 4 to 12 weeks [7]. Annual lipid monitoring is standard. These lab costs are covered by most insurance plans as preventive care.

Amlodipine's most common adverse effect is dose-dependent peripheral edema, reported in 1.8% of patients at 5 mg and 10.8% at 10 mg in the prescribing information [14]. Dizziness, flushing, and palpitations occur in 1% to 3% of patients. No routine lab monitoring is required for amlodipine beyond periodic blood pressure checks.

From a total cost-of-care perspective, amlodipine requires slightly less monitoring than atorvastatin. The difference is minor in absolute dollars, as lipid panels are inexpensive tests, but it is worth noting for patients managing tight budgets.

Clinical Scenarios: Who Gets What

Patient A: 55-year-old male, LDL 165 mg/dL, blood pressure 118/74. This patient needs atorvastatin. His blood pressure is normal, so amlodipine has no indication. Monthly cost: $4 to $10 for generic atorvastatin.

Patient B: 62-year-old female, LDL 95 mg/dL, blood pressure 158/92. This patient needs amlodipine (or another antihypertensive). Her LDL is at goal, so a statin may not be indicated unless her 10-year ASCVD risk score exceeds 7.5%. Monthly cost: $4 to $12 for generic amlodipine.

Patient C: 58-year-old male, LDL 142 mg/dL, blood pressure 152/88, type 2 diabetes. This patient needs both. He matches the ASCOT-LLA enrollment profile almost exactly. Monthly cost: $8 to $20 for both generics, or $15 to $40 for generic Caduet.

Patient D: 70-year-old female on Medicare, LDL 130 mg/dL, blood pressure 145/85, prior stroke. This patient needs high-intensity statin therapy (atorvastatin 40 to 80 mg) per AHA/ASA secondary prevention guidelines [15] plus blood pressure control to a target below 130/80. Copay for both drugs under Part D: $0 to $10 total per month.

The Bottom Line on Cost and Access

Generic atorvastatin and generic amlodipine are among the cheapest, most accessible prescription medications in the United States. Combined monthly out-of-pocket cost for both drugs at standard doses runs $8 to $20 at discount pharmacies, with most insured patients paying $0 to $10 in copays. The ASCOT-LLA trial demonstrated a 36% CHD risk reduction with atorvastatin 10 mg in hypertensive patients (P=0.0005), and ASCOT-BPLA showed amlodipine-based therapy reduced all-cause mortality by 11% versus atenolol (P=0.025). For the large population of patients with both dyslipidemia and hypertension, these two drugs prescribed together represent one of the highest-value interventions in cardiovascular medicine, costing less per month than a single fast-food meal while addressing two of the three leading modifiable risk factors for heart attack and stroke.